19 results
8-K
EX-10.1
SLRN
Acelyrin, Inc.
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
of privacy; false imprisonment; conversion; and disability benefits;
dany and all claims for violation of any federal, state, or municipal statute
8-K
EX-10.2
SLRN
Acelyrin, Inc.
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy
8-K
EX-10.1
SLRN
Acelyrin, Inc.
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;
d. any and all claims for violation of any federal
10-K
cxogeiflc0kl80a2z na
28 Mar 24
Annual report
4:21pm
8-K
EX-10.1
18n zib9wzwj
2 Aug 23
Departure of Directors or Certain Officers
5:05pm
10-Q
tilr4wg z5guzjjemqi
15 Jun 23
Quarterly report
4:19pm
424B4
i3qacxzmwmb3j
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
EX-1.1
w76th1
1 May 23
IPO registration (amended)
6:10am
S-1/A
rnkxy7y
1 May 23
IPO registration (amended)
6:10am
CORRESP
gd2syiubmycq
20 Apr 23
Correspondence with SEC
12:00am
S-1
EX-10.13
o1bntagq1 mo
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
x5fblut1bo l8gg
13 Apr 23
IPO registration
5:10pm
S-1
EX-10.2
hut0x0dx7a gd
13 Apr 23
IPO registration
5:10pm
S-1
z3iwzawi
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next